Barry G. Arnason to Multiple Sclerosis, Relapsing-Remitting
This is a "connection" page, showing publications Barry G. Arnason has written about Multiple Sclerosis, Relapsing-Remitting.
Connection Strength
1.326
-
Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
Score: 0.301
-
Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis. Arch Neurol. 2001 Jan; 58(1):87-90.
Score: 0.162
-
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. J Neurol. 2015 Nov; 262(11):2466-71.
Score: 0.111
-
Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study. Eur Neurol. 2014; 71(3-4):173-9.
Score: 0.100
-
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study. J Neurol. 2013 Jul; 260(7):1838-45.
Score: 0.094
-
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler. 2012 Feb; 18(2):181-95.
Score: 0.085
-
Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Mult Scler. 2011 Dec; 17(12):1504-13.
Score: 0.084
-
Tumour Necrosis Factor Neutralization in MS: A Cautionary Tale. Int MS J. 2011 May; 17(2):63-8.
Score: 0.083
-
Interferon ß-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011 Apr 05; 76(14):1222-8.
Score: 0.082
-
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10):889-97.
Score: 0.074
-
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Clin Ther. 2008 Jun; 30(6):1102-12.
Score: 0.068
-
Interferons in relapsing remitting multiple sclerosis. Lancet. 2003 May 24; 361(9371):1822; author reply 1823-4.
Score: 0.048
-
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Mult Scler. 2019 04; 25(4):565-573.
Score: 0.033